Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Pharmaceutical Administration and Regulations in Japan - Nihs
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
PMSB dated November 24, 2006<br />
(3) Guidel<strong>in</strong>es for Bioequivalence<br />
Test<strong>in</strong>g of Products with Different<br />
Dosage Forms (Notification No. 783<br />
of the Evaluation <strong>and</strong> Licens<strong>in</strong>g<br />
Division, PMSB dated May 31, 2001)<br />
(4) Guidel<strong>in</strong>es for Bioequivalence<br />
Test<strong>in</strong>g of Oral Solid Dosage Forms<br />
with Formulation Modifications<br />
(Notification No. 67 of the Evaluation<br />
<strong>and</strong> Licens<strong>in</strong>g Division, PMSB dated<br />
February 14, 2000, partially revised<br />
by Notification No. 786 of the<br />
Evaluation <strong>and</strong> Licens<strong>in</strong>g Division,<br />
PMSB dated May 31, 2001, <strong>and</strong><br />
Notification No. 1124004 of the<br />
Evaluation <strong>and</strong> Licens<strong>in</strong>g Division,<br />
PMSB dated) November 24, 2006.<br />
(5) Guidel<strong>in</strong>es for Bioequivalence<br />
Studies of Generic Products for<br />
Topical Dermatological Use<br />
(Notification No. 0707001 of the<br />
Evaluation <strong>and</strong> Licens<strong>in</strong>g Division,<br />
PMSB dated July 7, 2003, partially<br />
revised by Notification No. 1124004<br />
of the Evaluation <strong>and</strong> Licens<strong>in</strong>g<br />
Division, PMSB dated November 24,<br />
2006).<br />
(6) Guidel<strong>in</strong>es for Bioequivalence<br />
Test<strong>in</strong>g of New Additional Topical<br />
Dermatological Dosage Forms<br />
(Notification No. 1124001 of the<br />
Evaluation <strong>and</strong> Licens<strong>in</strong>g Division,<br />
<strong>Pharmaceutical</strong> <strong>Regulations</strong> <strong>in</strong> <strong>Japan</strong>:<br />
PMSB dated November 24, 2006).<br />
(7) Guidel<strong>in</strong>es for Bioequivalence<br />
Test<strong>in</strong>g of Topical Dermatological<br />
Dosage Forms with Formulation<br />
Modifications (Notification No.<br />
1101-1 of the Evaluation <strong>and</strong><br />
Licens<strong>in</strong>g Division, PMSB dated<br />
November 1, 2010).<br />
3.2 Cl<strong>in</strong>ical Studies<br />
1) Basic requirements<br />
The primary objectives of cl<strong>in</strong>ical<br />
studies are to evaluate therapeutic <strong>and</strong><br />
prophylactic efficacy of <strong>in</strong>vestigational<br />
new drugs for target diseases or<br />
symptoms as well as their risks <strong>and</strong><br />
possible ADRs <strong>in</strong> humans, <strong>and</strong> ultimately<br />
to assess their cl<strong>in</strong>ical usefulness based<br />
on a comparison of their efficacy <strong>and</strong><br />
safety. In perform<strong>in</strong>g cl<strong>in</strong>ical studies,<br />
<strong>in</strong>vestigators must give scientific <strong>and</strong><br />
ethical consideration to the subjects'<br />
human rights to m<strong>in</strong>imize their risk relative<br />
to the expected benefits.<br />
Guidance concern<strong>in</strong>g drug<br />
development strategies <strong>and</strong> evaluation<br />
processes has been issued <strong>in</strong> the three<br />
ICH regions. In 1998, General<br />
Considerations for Cl<strong>in</strong>ical Studies<br />
(Notification No. 380 of the Evaluation<br />
<strong>and</strong> Licens<strong>in</strong>g Division, PMSB dated April<br />
21, 1998, ICH E8) was prepared as one<br />
aspect of MHLW’s efforts to promote<br />
2011-3 - 83 -